| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | MIA1 |
| Uniprot No | Q61865 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-130aa |
| 氨基酸序列 | DRAMPKLA DWKLCADEEC SHPISMAVAL QDYVAPDCRF LTIYRGQVVY VFSKLKGRGR LFWGGSVQGG YYGDLAARLG YFPSSIVRED LTLKPGKIDM KTDQWDFYCQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIA1重组蛋白的3篇参考文献(文献标题及摘要为模拟概括，非真实文献)：
1. **标题**：*Recombinant MIA1 Protein Inhibits Melanoma Cell Invasion In Vitro*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统表达并纯化重组MIA1蛋白，发现其通过结合细胞表面整合素抑制黑色素瘤细胞的迁移和侵袭能力，提示其作为潜在抗转移治疗分子。
2. **标题**：*Structural Characterization and Functional Analysis of MIA1 in Tumor Extracellular Matrix Remodeling*
**作者**：Zhang L, et al.
**摘要**：利用昆虫细胞表达系统获得高纯度MIA1重组蛋白，通过晶体结构解析和体外实验揭示其通过SH3结构域与胞外基质蛋白相互作用，调控肿瘤微环境重塑。
3. **标题**：*MIA1 Recombinant Protein Attenuates Cartilage Degeneration in Osteoarthritis Models*
**作者**：Chen R, et al.
**摘要**：通过哺乳动物细胞表达MIA1重组蛋白，证明其可抑制软骨细胞凋亡和炎症因子释放，在骨关节炎小鼠模型中显著减缓软骨退变进程。
(注：以上内容为基于领域知识的模拟生成，实际文献需通过PubMed/Google Scholar等数据库以关键词“MIA1 recombinant protein”检索验证。)
**Background of MIA1 Recombinant Protein**
MIA1 (Melanoma Inhibitory Activity 1), also known as CD-RAP (Cartilage-Derived Retinoic Acid-Sensitive Protein), is a secreted protein initially identified in melanoma cells for its role in suppressing tumor progression and metastasis. Structurally, it belongs to the MIA/OTOR family, characterized by a conserved SH3 domain that facilitates interactions with extracellular matrix components and cell surface receptors. MIA1 is encoded by the *MIA1* gene and is physiologically expressed in cartilage, neural tissues, and certain epithelial cells, playing roles in cell adhesion, differentiation, and tissue remodeling.
Recombinant MIA1 protein is produced using genetic engineering techniques, often in bacterial or mammalian expression systems, to ensure high purity and bioactivity. Its study has gained momentum due to its dual role in cancer biology. While early studies highlighted its tumor-suppressive properties in melanoma by inhibiting cell migration and invasion, recent research reveals context-dependent oncogenic functions. For instance, MIA1 overexpression in breast, pancreatic, or colorectal cancers correlates with enhanced metastasis, chemoresistance, and poor prognosis, likely mediated through integrin-mediated signaling or modulation of MAPK/ERK pathways.
Beyond oncology, MIA1 is implicated in cartilage development and degenerative diseases. It regulates chondrocyte differentiation and matrix production, making it a potential biomarker for osteoarthritis or cartilage repair therapies. Additionally, its involvement in neuronal survival and axon guidance suggests relevance in neuroregeneration.
The development of recombinant MIA1 has enabled mechanistic studies, antibody production, and drug screening. However, conflicting data on its pro- and anti-tumor effects underscore the need for tissue- and context-specific investigations. Current research focuses on deciphering its molecular interactors, such as fibronectin or α4β1 integrin, and exploring therapeutic strategies targeting MIA1 in precision medicine. Overall, MIA1 recombinant protein serves as a critical tool for unraveling its multifaceted roles in health and disease.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
